MATTHEW FUENTES

Cited source text

Issues related to Pediatric Review Voucher (PRV); H.R. 10359, Priority for Pediatric Cures Act

H.R. 10628

Biosimilars Access and Affordability Act

Client: AMGEN, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act

Original LDA source filings (100)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

2026 · third_quarter · Q3

Firm income: $120,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues relating to Medicare Advantage; Issues related to the use of AI and its correlation to prior authorization and utilization management policies; S. 1105, No UPCODE Act; Issues related to Senate Finance Dear Colleague process

HCR

Health Issues

H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act; Issues related to surprise medical billing

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

Source: Senate LDA

Show 96 more cited filings

H.R. 1227

Alternatives to PAIN Act

Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; Kidney care issues; FY27 LHHS and Mil-Con appropriations report language

H.R. 1492

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

Client: GENENTECH USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process

H.R. 1492

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

Client: GENENTECH USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process

H.R. 1492

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

Client: GENENTECH USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act

H.R. 1672

Maintaining Investments in New Innovation Act

Client: GENENTECH USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process

H.R. 1672

Maintaining Investments in New Innovation Act

Client: GENENTECH USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process

H.R. 1672

Maintaining Investments in New Innovation Act

Client: GENENTECH USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act

H.R. 2484

Seniors’ Access to Critical Medications Act of 2025

Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 2484, Seniors Access to Critical Medications Act; Issues related to the extension of telehealth services; Issues related to site neutral payments; Issues related to 2024 Physician Fee Schedule and physician payment reform; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to in-office dispensing of medication regulations; H.R. 8163/S. 5180, Provider Reimbursement Stability Act

H.R. 2484

Seniors’ Access to Critical Medications Act of 2025

Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 2484, Seniors Access to Critical Medications Act; Issues related to the extension of telehealth services; Issues related to site neutral payments; Issues related to 2024 Physician Fee Schedule and physician payment reform; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to in-office dispensing of medication regulations

H.R. 2484

Seniors’ Access to Critical Medications Act of 2025

Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 2484, Seniors Access to Critical Medications Act; Issues related to the extension of telehealth services; Issues related to site neutral payments; Issues related to 2024 Physician Fee Schedule and physician payment reform; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to in-office dispensing of medication regulations

H.R. 3164

Ensuring Community Access to Pharmacist Services Act

Client: AMERICAN MEDICAL ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Physician Fee Schedule and physician payment reform; H.R. 879, Medicare Patient Access and Practice Stabilization Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services Act; Issues related to Provider Reimbursement Stability Act and Merit Based Incentive Payments System (MIPS) reform; Issues related to Senate Finance Dear Colleague process

H.R. 3164

Ensuring Community Access to Pharmacist Services Act

Client: AMERICAN MEDICAL ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to 2024 Physician Fee Schedule and physician payment reform; H.R. 879, Medicare Patient Access and Practice Stabilization Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services Act; Issues related to Provider Reimbursement Stability Act and Merit Based Incentive Payments System (MIPS) reform; Issues related to Senate Finance Dear Colleague process

H.R. 3164

Ensuring Community Access to Pharmacist Services Act

Client: AMERICAN MEDICAL ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Physician Fee Schedule and physician payment reform; H.R. 879, Medicare Patient Access and Practice Stabilization Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services Act; H.R. 8163/S. 5180, Provider Reimbursement Stability Act; Issues related to Provider Reimbursement Stability Act and Merit Based Incentive Payments System (MIPS) reform; Issues related to Senate Finance Dear Colleague process

H.R. 3467

To amend title XVIII to reform the Medicare Advantage program.

Client: NATIONAL ALLIANCE FOR CARE AT HOME · Firm: AVENUE SOLUTIONS

Cited source text

Medicare Home Health benefit; Medicaid Home and Community-Based Services (HCBS) benefits; Medicare Hospice benefit; Home Health Perspective Payment System (HH PPS) Final Rule for CY 2026 (CMS-1828-F); H.R. 3467, To amend title XVIII to reform the Medicare Advantage program; H.R. 5142, Home Health Stabilization Act of 2025; Hospice MA Carve-in

H.R. 3467

To amend title XVIII to reform the Medicare Advantage program.

Client: NATIONAL ALLIANCE FOR CARE AT HOME · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 8883, Protecting Seniors and Stopping Fraudsters Act; Medicare Home Health benefit; Medicaid Home and Community-Based Services (HCBS) benefits; Medicare Hospice benefit; Home Health Perspective Payment System (HH PPS) Final Rule for CY 2026 (CMS-1828-F); H.R. 3467, To amend title XVIII to reform the Medicare Advantage program; H.R. 5142, Home Health Stabilization Act of 2025; Hospice MA Carve-in; Issues related to Medicare and Medicaid fraud; Issues related to Senate Finance Dear Colleague Process

H.R. 3467

To amend title XVIII to reform the Medicare Advantage program.

Client: NATIONAL ALLIANCE FOR CARE AT HOME · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 8883, Protecting Seniors and Stopping Fraudsters Act; Medicare Home Health benefit; Medicaid Home and Community-Based Services (HCBS) benefits; Medicare Hospice benefit; H.R. 3467, To amend title XVIII to reform the Medicare Advantage program; H.R. 5142, Home Health Stabilization Act of 2025; Hospice Medicare Advantage Carve-in; Issues related to Medicare and Medicaid fraud; Issues related to Senate Finance Dear Colleague Process; Medicare, Medicaid, and Children's Health Insurance Programs: Announcement of Nationwide Temporary Moratoria on Enrollment of Home Health Agencies (HHAs) CMS issued on 5/13/26; Medicare, Medicaid, and Children's Health Insurance Programs: Announcement of Nationwide Temporary Moratorium on Enrollment of Hospices CMS issued on 5/13/26; Calendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the Expanded HH Value-Based Purchasing Model; Medicare Provider Enrollment, Durable Medical Equipment (DME), and DME, Prosthetics, Orthotics, and Supplies (DMEPOS) Policies; S. 5250, Medicare Home Health Payment Integrity and Protection Act; DEAs registration pathway letting practitioners prescribe controlled substances via telemedicine without a prior in-person evaluation under the Ryan Haight Act; Medicare Advantage Home Health Network Adequacy; H.R. 8375, S. 4384, Medicare Advantage Improvement Act of 2026

Protecting Patient Access to Cancer and Complex Therapies Act

Client: AMGEN, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act

Protecting Patient Access to Cancer and Complex Therapies Act

Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 2484, Seniors Access to Critical Medications Act; Issues related to the extension of telehealth services; Issues related to site neutral payments; Issues related to 2024 Physician Fee Schedule and physician payment reform; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to in-office dispensing of medication regulations

Protecting Patient Access to Cancer and Complex Therapies Act

Client: MERCK & CO. INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act

Protecting Patient Access to Cancer and Complex Therapies Act

Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process; Issues related to the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the Orphan Cures Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA); Issues related to Most Favored Nation (MFN)

Protecting Patient Access to Cancer and Complex Therapies Act

Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 2484, Seniors Access to Critical Medications Act; Issues related to the extension of telehealth services; Issues related to site neutral payments; Issues related to 2024 Physician Fee Schedule and physician payment reform; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to in-office dispensing of medication regulations; H.R. 8163/S. 5180, Provider Reimbursement Stability Act

Protecting Patient Access to Cancer and Complex Therapies Act

Client: MERCK & CO. INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act

Protecting Patient Access to Cancer and Complex Therapies Act

Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act

Protecting Patient Access to Cancer and Complex Therapies Act

Client: GENENTECH USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process

Protecting Patient Access to Cancer and Complex Therapies Act

Client: GENENTECH USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process

Protecting Patient Access to Cancer and Complex Therapies Act

Client: AMGEN, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related To S. 5459, The Biosimilar Access and Affordability Act; Issues related to Senate Finance Dear Colleague process

Protecting Patient Access to Cancer and Complex Therapies Act

Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process; Issues related to the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the Orphan Cures Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA)

Protecting Patient Access to Cancer and Complex Therapies Act

Client: GENENTECH USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act

Protecting Patient Access to Cancer and Complex Therapies Act

Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 2484, Seniors Access to Critical Medications Act; Issues related to the extension of telehealth services; Issues related to site neutral payments; Issues related to 2024 Physician Fee Schedule and physician payment reform; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to in-office dispensing of medication regulations

H.R. 5142

Home Health Stabilization Act of 2025

Client: NATIONAL ALLIANCE FOR CARE AT HOME · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 8883, Protecting Seniors and Stopping Fraudsters Act; Medicare Home Health benefit; Medicaid Home and Community-Based Services (HCBS) benefits; Medicare Hospice benefit; H.R. 3467, To amend title XVIII to reform the Medicare Advantage program; H.R. 5142, Home Health Stabilization Act of 2025; Hospice Medicare Advantage Carve-in; Issues related to Medicare and Medicaid fraud; Issues related to Senate Finance Dear Colleague Process; Medicare, Medicaid, and Children's Health Insurance Programs: Announcement of Nationwide Temporary Moratoria on Enrollment of Home Health Agencies (HHAs) CMS issued on 5/13/26; Medicare, Medicaid, and Children's Health Insurance Programs: Announcement of Nationwide Temporary Moratorium on Enrollment of Hospices CMS issued on 5/13/26; Calendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the Expanded HH Value-Based Purchasing Model; Medicare Provider Enrollment, Durable Medical Equipment (DME), and DME, Prosthetics, Orthotics, and Supplies (DMEPOS) Policies; S. 5250, Medicare Home Health Payment Integrity and Protection Act; DEAs registration pathway letting practitioners prescribe controlled substances via telemedicine without a prior in-person evaluation under the Ryan Haight Act; Medicare Advantage Home Health Network Adequacy; H.R. 8375, S. 4384, Medicare Advantage Improvement Act of 2026

H.R. 5142

Home Health Stabilization Act of 2025

Client: NATIONAL ALLIANCE FOR CARE AT HOME · Firm: AVENUE SOLUTIONS

Cited source text

Medicare Home Health benefit; Medicaid Home and Community-Based Services (HCBS) benefits; Medicare Hospice benefit; Home Health Perspective Payment System (HH PPS) Final Rule for CY 2026 (CMS-1828-F); H.R. 3467, To amend title XVIII to reform the Medicare Advantage program; H.R. 5142, Home Health Stabilization Act of 2025; Hospice MA Carve-in

H.R. 5142

Home Health Stabilization Act of 2025

Client: NATIONAL ALLIANCE FOR CARE AT HOME · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 8883, Protecting Seniors and Stopping Fraudsters Act; Medicare Home Health benefit; Medicaid Home and Community-Based Services (HCBS) benefits; Medicare Hospice benefit; Home Health Perspective Payment System (HH PPS) Final Rule for CY 2026 (CMS-1828-F); H.R. 3467, To amend title XVIII to reform the Medicare Advantage program; H.R. 5142, Home Health Stabilization Act of 2025; Hospice MA Carve-in; Issues related to Medicare and Medicaid fraud; Issues related to Senate Finance Dear Colleague Process

Ensuring Patient Access to Critical Breakthrough Products Act

Client: SIEMENS MEDICAL SOLUTIONS USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Monitor issues related to site neutral payments; Monitor issues related to physician payment cuts; Monitor issues related to clinical lab tests; H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Ensuring Patient Access to Critical Breakthrough Products Act

Client: EDWARDS LIFESCIENCES LLC · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to CMSs draft coverage policy for transcatheter aortic valve replacement (TAVR) issued June 15, 2026; Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process

Ensuring Patient Access to Critical Breakthrough Products Act

Client: EDWARDS LIFESCIENCES LLC · Firm: AVENUE SOLUTIONS

Cited source text

Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders; Issues related to Senate Finance Dear Colleague process

Ensuring Patient Access to Critical Breakthrough Products Act

Client: SIEMENS MEDICAL SOLUTIONS USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Monitor issues related to site neutral payments; Monitor issues related to physician payment cuts; Monitor issues related to clinical lab tests; H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process

Ensuring Patient Access to Critical Breakthrough Products Act

Client: EDWARDS LIFESCIENCES LLC · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to CMSs draft coverage policy for transcatheter aortic valve replacement (TAVR) issued June 15, 2026; Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process

Ensuring Patient Access to Critical Breakthrough Products Act

Client: SIEMENS MEDICAL SOLUTIONS USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Monitor issues related to physician payment cuts; Monitor issues related to clinical lab tests; H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process; S. 1399, Health Tech Investment Act

H.R. 5526

Biosimilar Red Tape Elimination Act

Client: AMGEN, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act

H.R. 5526

Biosimilar Red Tape Elimination Act

Client: AMGEN, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related To S. 5459, The Biosimilar Access and Affordability Act; Issues related to Senate Finance Dear Colleague process

Patients Deserve Price Tags Act

Client: BLUE CROSS BLUE SHIELD ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Healthcare affordability platform; Issues related to Senate Finance Dear Colleague process; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act; Issues related to surprise medical billing

Patients Deserve Price Tags Act

Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to 340b; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act

Patients Deserve Price Tags Act

Client: BLUE CROSS BLUE SHIELD ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Healthcare affordability platform; Issues related to Senate Finance Dear Colleague process; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act; Issues related to surprise medical billing

Patients Deserve Price Tags Act

Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to 340b; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act

Patients Deserve Price Tags Act

Client: MARYLAND HOSPITAL ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to health workforce, including H1B visa and student loan reform; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act

Patients Deserve Price Tags Act

Client: UNITEDHEALTH GROUP INC · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act; Issues related to surprise medical billing

Patients Deserve Price Tags Act

Client: MARYLAND HOSPITAL ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to health workforce, including H1B visa and student loan reform; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act

Patients Deserve Price Tags Act

Client: UNITEDHEALTH GROUP INC · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act; Issues related to surprise medical billing

H.R. 6197

Health Tech Investment Act

Client: SIEMENS MEDICAL SOLUTIONS USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to healthcare data privacy; Issues related to Artificial Intelligence within the healthcare sector; H.R. 6197/S. 1399, Health Tech Investment Act

H.R. 7118

Genomic Answers for Children’s Health Act of 2026

Client: ILLUMINA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to genomic sequencing; H.R. 7118, Genomic Answers for Childrens Health Act of 2026

H.R. 8163

Provider Reimbursement Stability Act of 2026

Client: AMERICAN MEDICAL ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Physician Fee Schedule and physician payment reform; H.R. 879, Medicare Patient Access and Practice Stabilization Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services Act; H.R. 8163/S. 5180, Provider Reimbursement Stability Act; Issues related to Provider Reimbursement Stability Act and Merit Based Incentive Payments System (MIPS) reform; Issues related to Senate Finance Dear Colleague process

H.R. 8163

Provider Reimbursement Stability Act of 2026

Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 2484, Seniors Access to Critical Medications Act; Issues related to the extension of telehealth services; Issues related to site neutral payments; Issues related to 2024 Physician Fee Schedule and physician payment reform; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to in-office dispensing of medication regulations; H.R. 8163/S. 5180, Provider Reimbursement Stability Act

H.R. 8375

Medicare Advantage Improvement Act of 2026

Client: NATIONAL ALLIANCE FOR CARE AT HOME · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 8883, Protecting Seniors and Stopping Fraudsters Act; Medicare Home Health benefit; Medicaid Home and Community-Based Services (HCBS) benefits; Medicare Hospice benefit; H.R. 3467, To amend title XVIII to reform the Medicare Advantage program; H.R. 5142, Home Health Stabilization Act of 2025; Hospice Medicare Advantage Carve-in; Issues related to Medicare and Medicaid fraud; Issues related to Senate Finance Dear Colleague Process; Medicare, Medicaid, and Children's Health Insurance Programs: Announcement of Nationwide Temporary Moratoria on Enrollment of Home Health Agencies (HHAs) CMS issued on 5/13/26; Medicare, Medicaid, and Children's Health Insurance Programs: Announcement of Nationwide Temporary Moratorium on Enrollment of Hospices CMS issued on 5/13/26; Calendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the Expanded HH Value-Based Purchasing Model; Medicare Provider Enrollment, Durable Medical Equipment (DME), and DME, Prosthetics, Orthotics, and Supplies (DMEPOS) Policies; S. 5250, Medicare Home Health Payment Integrity and Protection Act; DEAs registration pathway letting practitioners prescribe controlled substances via telemedicine without a prior in-person evaluation under the Ryan Haight Act; Medicare Advantage Home Health Network Adequacy; H.R. 8375, S. 4384, Medicare Advantage Improvement Act of 2026

H.R. 842

Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

Client: GRAIL, INC. · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 842/S. 339, Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

H.R. 879

Medicare Patient Access and Practice Stabilization Act of 2025

Client: AMERICAN MEDICAL ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Physician Fee Schedule and physician payment reform; H.R. 879, Medicare Patient Access and Practice Stabilization Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services Act; Issues related to Provider Reimbursement Stability Act and Merit Based Incentive Payments System (MIPS) reform; Issues related to Senate Finance Dear Colleague process

H.R. 879

Medicare Patient Access and Practice Stabilization Act of 2025

Client: AMERICAN MEDICAL ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to 2024 Physician Fee Schedule and physician payment reform; H.R. 879, Medicare Patient Access and Practice Stabilization Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services Act; Issues related to Provider Reimbursement Stability Act and Merit Based Incentive Payments System (MIPS) reform; Issues related to Senate Finance Dear Colleague process

H.R. 879

Medicare Patient Access and Practice Stabilization Act of 2025

Client: AMERICAN MEDICAL ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Physician Fee Schedule and physician payment reform; H.R. 879, Medicare Patient Access and Practice Stabilization Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services Act; H.R. 8163/S. 5180, Provider Reimbursement Stability Act; Issues related to Provider Reimbursement Stability Act and Merit Based Incentive Payments System (MIPS) reform; Issues related to Senate Finance Dear Colleague process

H.R. 8883

Protecting Seniors and Stopping Fraudsters Act

Client: NATIONAL ALLIANCE FOR CARE AT HOME · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 8883, Protecting Seniors and Stopping Fraudsters Act; Medicare Home Health benefit; Medicaid Home and Community-Based Services (HCBS) benefits; Medicare Hospice benefit; Home Health Perspective Payment System (HH PPS) Final Rule for CY 2026 (CMS-1828-F); H.R. 3467, To amend title XVIII to reform the Medicare Advantage program; H.R. 5142, Home Health Stabilization Act of 2025; Hospice MA Carve-in; Issues related to Medicare and Medicaid fraud; Issues related to Senate Finance Dear Colleague Process

H.R. 8883

Protecting Seniors and Stopping Fraudsters Act

Client: NATIONAL ALLIANCE FOR CARE AT HOME · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 8883, Protecting Seniors and Stopping Fraudsters Act; Medicare Home Health benefit; Medicaid Home and Community-Based Services (HCBS) benefits; Medicare Hospice benefit; H.R. 3467, To amend title XVIII to reform the Medicare Advantage program; H.R. 5142, Home Health Stabilization Act of 2025; Hospice Medicare Advantage Carve-in; Issues related to Medicare and Medicaid fraud; Issues related to Senate Finance Dear Colleague Process; Medicare, Medicaid, and Children's Health Insurance Programs: Announcement of Nationwide Temporary Moratoria on Enrollment of Home Health Agencies (HHAs) CMS issued on 5/13/26; Medicare, Medicaid, and Children's Health Insurance Programs: Announcement of Nationwide Temporary Moratorium on Enrollment of Hospices CMS issued on 5/13/26; Calendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the Expanded HH Value-Based Purchasing Model; Medicare Provider Enrollment, Durable Medical Equipment (DME), and DME, Prosthetics, Orthotics, and Supplies (DMEPOS) Policies; S. 5250, Medicare Home Health Payment Integrity and Protection Act; DEAs registration pathway letting practitioners prescribe controlled substances via telemedicine without a prior in-person evaluation under the Ryan Haight Act; Medicare Advantage Home Health Network Adequacy; H.R. 8375, S. 4384, Medicare Advantage Improvement Act of 2026

Lower Costs, More Transparency Act of 2026

Client: UNITEDHEALTH GROUP INC · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act; Issues related to surprise medical billing

Lower Costs, More Transparency Act of 2026

Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to 340b; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act

Lower Costs, More Transparency Act of 2026

Client: BLUE CROSS BLUE SHIELD ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Healthcare affordability platform; Issues related to Senate Finance Dear Colleague process; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act; Issues related to surprise medical billing

Lower Costs, More Transparency Act of 2026

Client: UNITEDHEALTH GROUP INC · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act; Issues related to surprise medical billing

Lower Costs, More Transparency Act of 2026

Client: BLUE CROSS BLUE SHIELD ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Healthcare affordability platform; Issues related to Senate Finance Dear Colleague process; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act; Issues related to surprise medical billing

Lower Costs, More Transparency Act of 2026

Client: MARYLAND HOSPITAL ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to health workforce, including H1B visa and student loan reform; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act

Lower Costs, More Transparency Act of 2026

Client: MARYLAND HOSPITAL ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to health workforce, including H1B visa and student loan reform; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act

Lower Costs, More Transparency Act of 2026

Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to 340b; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act

H.R. 946

ORPHAN Cures Act

Client: JAZZ PHARMACEUTICALS, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to implementation of the Inflation Reduction Act of 2022; Issues related to Senate Finance Dear Colleague process; H.R. 946/S. 1862, ORPHAN Cures Act

H.R. 946

ORPHAN Cures Act

Client: JAZZ PHARMACEUTICALS, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 946/S. 1862, ORPHAN Cures Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA)

Tax Exempt Hospital Transparency Act

Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to 340b; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act

Tax Exempt Hospital Transparency Act

Client: BLUE CROSS BLUE SHIELD ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Healthcare affordability platform; Issues related to Senate Finance Dear Colleague process; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act; Issues related to surprise medical billing

Tax Exempt Hospital Transparency Act

Client: BLUE CROSS BLUE SHIELD ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Healthcare affordability platform; Issues related to Senate Finance Dear Colleague process; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act; Issues related to surprise medical billing

Tax Exempt Hospital Transparency Act

Client: UNITEDHEALTH GROUP INC · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act; Issues related to surprise medical billing

Tax Exempt Hospital Transparency Act

Client: MARYLAND HOSPITAL ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to health workforce, including H1B visa and student loan reform; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act

Tax Exempt Hospital Transparency Act

Client: UNITEDHEALTH GROUP INC · Firm: AVENUE SOLUTIONS

Cited source text

H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act; Issues related to surprise medical billing

Tax Exempt Hospital Transparency Act

Client: MARYLAND HOSPITAL ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to health workforce, including H1B visa and student loan reform; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act

Tax Exempt Hospital Transparency Act

Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to 340b; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act

No UPCODE Act

Client: SCAN HEALTH PLAN · Firm: AVENUE SOLUTIONS

Cited source text

Medicare and Medicaid dual eligible integration; Monitoring of Medicare Advantage, particularly as it relates to changes in coding intensity, benchmarks, health risk assessments, prompt pay, and brokers; Issues related to Medicare Advantage marketing practices, provider directories and prior authorization; S. 1105, No UPCODE Act; Issues related to street medicine; MedPAC nomination process; Issues related to Senate Finance Dear Colleague process

No UPCODE Act

Client: UNITEDHEALTH GROUP INC · Firm: AVENUE SOLUTIONS

Cited source text

Issues relating to Medicare Advantage; Issues related to the use of AI and its correlation to prior authorization and utilization management policies; S. 1105, No UPCODE Act; Issues related to Senate Finance Dear Colleague process

No UPCODE Act

Client: BLUE CROSS BLUE SHIELD ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Medicare Advantage; Issues related to site neutral payments; Issues related to PBM reforms; S. 1105, No UPCODE Act

No UPCODE Act

Client: UNITEDHEALTH GROUP INC · Firm: AVENUE SOLUTIONS

Cited source text

Issues relating to Medicare Advantage; Issues related to the use of AI and its correlation to prior authorization and utilization management policies; S. 1105, No UPCODE Act; Issues related to Senate Finance Dear Colleague process

No UPCODE Act

Client: SCAN HEALTH PLAN · Firm: AVENUE SOLUTIONS

Cited source text

Medicare and Medicaid dual eligible integration; Monitoring of Medicare Advantage, particularly as it relates to changes in coding intensity, benchmarks, health risk assessments, prompt pay, and brokers; Issues related to Medicare Advantage marketing practices, provider directories and prior authorization; S. 1105, No UPCODE Act; Issues related to street medicine; MedPAC nomination process; Issues related to Senate Finance Dear Colleague process

No UPCODE Act

Client: UNITEDHEALTH GROUP INC · Firm: AVENUE SOLUTIONS

Cited source text

Issues relating to Medicare Advantage; Issues related to the use of AI and its correlation to prior authorization and utilization management policies; S. 1105, No UPCODE Act; Issues related to Senate Finance Dear Colleague process

No UPCODE Act

Client: BLUE CROSS BLUE SHIELD ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Medicare Advantage; Issues related to site neutral payments; Issues related to PBM reforms; S. 1105, No UPCODE Act

No UPCODE Act

Client: SCAN HEALTH PLAN · Firm: AVENUE SOLUTIONS

Cited source text

Medicare and Medicaid dual eligible integration; Monitoring of Medicare Advantage, particularly as it relates to changes in coding intensity, benchmarks, health risk assessments, prompt pay, and brokers; Issues related to Medicare Advantage marketing practices, provider directories and prior authorization; S. 1105, No UPCODE Act; Issues related to street medicine; MedPAC nomination process; Issues related to Senate Finance Dear Colleague process

No UPCODE Act

Client: BLUE CROSS BLUE SHIELD ASSOCIATION · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Medicare Advantage; Issues related to site neutral payments; Issues related to PBM reforms; S. 1105, No UPCODE Act

S. 1399

Health Tech Investment Act

Client: SIEMENS MEDICAL SOLUTIONS USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to healthcare data privacy; Issues related to Artificial Intelligence within the healthcare sector; H.R. 6197/S. 1399, Health Tech Investment Act

S. 1399

Health Tech Investment Act

Client: SIEMENS MEDICAL SOLUTIONS USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Monitor issues related to physician payment cuts; Monitor issues related to clinical lab tests; H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process; S. 1399, Health Tech Investment Act

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Client: SIEMENS MEDICAL SOLUTIONS USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Monitor issues related to physician payment cuts; Monitor issues related to clinical lab tests; H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process; S. 1399, Health Tech Investment Act

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Client: EDWARDS LIFESCIENCES LLC · Firm: AVENUE SOLUTIONS

Cited source text

Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders; Issues related to Senate Finance Dear Colleague process

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Client: SIEMENS MEDICAL SOLUTIONS USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Monitor issues related to site neutral payments; Monitor issues related to physician payment cuts; Monitor issues related to clinical lab tests; H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Client: EDWARDS LIFESCIENCES LLC · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to CMSs draft coverage policy for transcatheter aortic valve replacement (TAVR) issued June 15, 2026; Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Client: EDWARDS LIFESCIENCES LLC · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to CMSs draft coverage policy for transcatheter aortic valve replacement (TAVR) issued June 15, 2026; Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Client: SIEMENS MEDICAL SOLUTIONS USA, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Monitor issues related to site neutral payments; Monitor issues related to physician payment cuts; Monitor issues related to clinical lab tests; H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process

S. 1862

ORPHAN Cures Act

Client: JAZZ PHARMACEUTICALS, INC. · Firm: AVENUE SOLUTIONS

Cited source text

Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to implementation of the Inflation Reduction Act of 2022; Issues related to Senate Finance Dear Colleague process; H.R. 946/S. 1862, ORPHAN Cures Act

S. 1862

ORPHAN Cures Act

Client: JAZZ PHARMACEUTICALS, INC. · Firm: AVENUE SOLUTIONS

PARTNERSHIP FOR MEDICAID HOME-BASED CARE (PMHC) via AVENUE SOLUTIONS

Cited source text

Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 946/S. 1862, ORPHAN Cures Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA)

Show 96 more original filings

2026 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to Medicaid Home and Community-Based Services (HCBS); Issues related to Senate Finance Dear Colleague process

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

OMEROS CORPORATION via AVENUE SOLUTIONS

2026 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to Pediatric Review Voucher (PRV); H.R. 10359, Priority for Pediatric Cures Act

NATIONAL ALLIANCE FOR CARE AT HOME via AVENUE SOLUTIONS

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

H.R. 8883, Protecting Seniors and Stopping Fraudsters Act; Medicare Home Health benefit; Medicaid Home and Community-Based Services (HCBS) benefits; Medicare Hospice benefit; H.R. 3467, To amend title XVIII to reform the Medicare Advantage program; H.R. 5142, Home Health Stabilization Act of 2025; Hospice Medicare Advantage Carve-in; Issues related to Medicare and Medicaid fraud; Issues related to Senate Finance Dear Colleague Process; Medicare, Medicaid, and Children's Health Insurance Programs: Announcement of Nationwide Temporary Moratoria on Enrollment of Home Health Agencies (HHAs) CMS issued on 5/13/26; Medicare, Medicaid, and Children's Health Insurance Programs: Announcement of Nationwide Temporary Moratorium on Enrollment of Hospices CMS issued on 5/13/26; Calendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the Expanded HH Value-Based Purchasing Model; Medicare Provider Enrollment, Durable Medical Equipment (DME), and DME, Prosthetics, Orthotics, and Supplies (DMEPOS) Policies; S. 5250, Medicare Home Health Payment Integrity and Protection Act; DEAs registration pathway letting practitioners prescribe controlled substances via telemedicine without a prior in-person evaluation under the Ryan Haight Act; Medicare Advantage Home Health Network Adequacy; H.R. 8375, S. 4384, Medicare Advantage Improvement Act of 2026

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to the Vaccine Injury Compensation Program (VICP); Issues related to vaccine safety and approval; Issues related to FDA's approval of Moderna's flu vaccine; Issues related to Messenger RNA (mRNA) therapies

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

MEDICAL INFORMATION TECHNOLOGY, INC. (MEDITECH) via AVENUE SOLUTIONS

2026 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to vaccines; Issues related to 340b

MMM

Medicare/Medicaid

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to electronic health records, including TEFCA, HTI-5, interoperability standards and rural health

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) via AVENUE SOLUTIONS

2026 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC); Issues related to Senate Finance Dear Colleague process

HCR

Health Issues

Issues related to health workforce, including H1B visa and student loan reform; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to 340b; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act

MMM

Medicare/Medicaid

H.R. 2484, Seniors Access to Critical Medications Act; Issues related to the extension of telehealth services; Issues related to site neutral payments; Issues related to 2024 Physician Fee Schedule and physician payment reform; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to in-office dispensing of medication regulations; H.R. 8163/S. 5180, Provider Reimbursement Stability Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 946/S. 1862, ORPHAN Cures Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA)

HCR

Health Issues

Drug safety, prescription drug abuse, value of prescription drugs; Issues related to drug pricing, including orphan drugs

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to 340B

MMM

Medicare/Medicaid

Issues related to Medicaid rebates; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to CMMI demos (Guarding U.S. Medicare Against Rising Drug Costs (GUARD) and Global Benchmark for Efficient Drug Pricing (GLOBE)); Issues related to Senate Finance Dear Colleague process; Education around access to innovative therapies in dermatology; Issues related to the Orphan Cures Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ILLUMINA, INC. via AVENUE SOLUTIONS

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to genomic sequencing; H.R. 7118, Genomic Answers for Childrens Health Act of 2026

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to home care and home and community based services (HCBS); Ensuring Access to Medicaid Services (CMS-2442-F); Home Health Perspective Payment System (HH PPS) Final Rule for CY 2026 (CMS-1828-F); Issues related to Senate Finance Dear Colleague process

2026 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to multi-cancer early detection screening; Issues related to P.L. 119-75 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to 340b drug pricing program

MMM

Medicare/Medicaid

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

DISTRICT OF COLUMBIA HOSPITAL ASSOCIATION via AVENUE SOLUTIONS

2026 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to CMSs draft coverage policy for transcatheter aortic valve replacement (TAVR) issued June 15, 2026; Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to DC Hospitals and Medicaid formula; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC)

TAX

Taxation/Internal Revenue Code

Issues related to DC taxes

COMPASS PATHWAYS, INC. via AVENUE SOLUTIONS

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to innovative treatment for mental health and PTSD

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

BLUE CROSS BLUE SHIELD ASSOCIATION via AVENUE SOLUTIONS

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to prescription drugs, including 340B program

MMM

Medicare/Medicaid

Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process; Issues related to the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the Orphan Cures Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA); Issues related to Most Favored Nation (MFN)

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · third_quarter · Q3

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to Medicare Advantage; Issues related to site neutral payments; Issues related to PBM reforms; S. 1105, No UPCODE Act

HCR

Health Issues

Healthcare affordability platform; Issues related to Senate Finance Dear Colleague process; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act; Issues related to surprise medical billing

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

APOLLO GLOBAL MANAGEMENT, INC. via AVENUE SOLUTIONS

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to hospital management.

AMGEN, INC. via AVENUE SOLUTIONS

2026 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

VERTEX PHARMACEUTICALS INCORPORATED via AVENUE SOLUTIONS

2026 · third_quarter · Q3

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to Physician Fee Schedule and physician payment reform; H.R. 879, Medicare Patient Access and Practice Stabilization Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services Act; H.R. 8163/S. 5180, Provider Reimbursement Stability Act; Issues related to Provider Reimbursement Stability Act and Merit Based Incentive Payments System (MIPS) reform; Issues related to Senate Finance Dear Colleague process

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

OMEROS CORPORATION via AVENUE SOLUTIONS

2026 · third_quarter · RA

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to Pediatric Review Voucher (PRV)

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Monitor issues related to 340b;

MMM

Medicare/Medicaid

H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; Kidney care issues; FY27 LHHS and Mil-Con appropriations report language

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

TAKEDA PHARMACEUTICALS AMERICA, INC. via AVENUE SOLUTIONS

2026 · second_quarter · Q2

Firm income: $120,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

HCR

Health Issues

H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act; Issues related to surprise medical billing

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · second_quarter · Q2

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to drug pricing and reimbursement for prescription drugs

SIEMENS MEDICAL SOLUTIONS USA, INC. via AVENUE SOLUTIONS

2026 · second_quarter · Q2

Firm income: $70,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to healthcare data privacy; Issues related to Artificial Intelligence within the healthcare sector; H.R. 6197/S. 1399, Health Tech Investment Act

MMM

Medicare/Medicaid

Monitor issues related to site neutral payments; Monitor issues related to physician payment cuts; Monitor issues related to clinical lab tests; H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

SCAN HEALTH PLAN via AVENUE SOLUTIONS

2026 · second_quarter · Q2

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Medicare and Medicaid dual eligible integration; Monitoring of Medicare Advantage, particularly as it relates to changes in coding intensity, benchmarks, health risk assessments, prompt pay, and brokers; Issues related to Medicare Advantage marketing practices, provider directories and prior authorization; S. 1105, No UPCODE Act; Issues related to street medicine; MedPAC nomination process; Issues related to Senate Finance Dear Colleague process

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PARTNERSHIP FOR MEDICAID HOME-BASED CARE (PMHC) via AVENUE SOLUTIONS

2026 · second_quarter · Q2

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to Medicaid Home and Community-Based Services (HCBS); Issues related to Senate Finance Dear Colleague process

NATIONAL ALLIANCE FOR CARE AT HOME via AVENUE SOLUTIONS

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

H.R. 8883, Protecting Seniors and Stopping Fraudsters Act; Medicare Home Health benefit; Medicaid Home and Community-Based Services (HCBS) benefits; Medicare Hospice benefit; Home Health Perspective Payment System (HH PPS) Final Rule for CY 2026 (CMS-1828-F); H.R. 3467, To amend title XVIII to reform the Medicare Advantage program; H.R. 5142, Home Health Stabilization Act of 2025; Hospice MA Carve-in; Issues related to Medicare and Medicaid fraud; Issues related to Senate Finance Dear Colleague Process

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · second_quarter · Q2

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to the Vaccine Injury Compensation Program (VICP); Issues related to vaccine safety and approval; Issues related to FDA's delay in reviewing Moderna's flu vaccine

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

MEDICAL INFORMATION TECHNOLOGY, INC. (MEDITECH) via AVENUE SOLUTIONS

2026 · second_quarter · Q2

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

HCR

Health Issues

Issues related to vaccines; Issues related to 340b

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · second_quarter · Q2

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to electronic health records, including TEFCA, HTI-5, interoperability standards and rural health; Issues related to Senator Wyden's letter to Electronic Health Record (EHR) companies and the adoption of privacy measures to protect patient data

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) via AVENUE SOLUTIONS

2026 · second_quarter · Q2

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

HCR

Health Issues

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

HCR

Health Issues

Issues related to 340b; H.R. 9393, Lower Costs, More Transparency Act; H.R. 5582 / S. 2355, Patients Deserve Price Tags Act; H.R. 9504, Tax Exempt Hospital Transparency Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · second_quarter · Q2

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to implementation of the Inflation Reduction Act of 2022; Issues related to Senate Finance Dear Colleague process; H.R. 946/S. 1862, ORPHAN Cures Act

HCR

Health Issues

Drug safety, prescription drug abuse, value of prescription drugs; Issues related to drug pricing, including orphan drugs

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

HCR

Health Issues

Issues related to 340b

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · second_quarter · Q2

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · second_quarter · Q2

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to multi-cancer early detection screening; Issues related to P.L. 119-75 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · second_quarter · Q2

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to 340b drug pricing program

MMM

Medicare/Medicaid

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

DISTRICT OF COLUMBIA HOSPITAL ASSOCIATION via AVENUE SOLUTIONS

2026 · second_quarter · Q2

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · second_quarter · Q2

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

TAX

Taxation/Internal Revenue Code

Issues related to DC taxes

MMM

Medicare/Medicaid

COMPASS PATHWAYS, INC. via AVENUE SOLUTIONS

2026 · second_quarter · Q2

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to innovative treatment for mental health and PTSD

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

BLUE CROSS BLUE SHIELD ASSOCIATION via AVENUE SOLUTIONS

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to prescription drugs

MMM

Medicare/Medicaid

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · second_quarter · Q2

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to Medicare Advantage; Issues related to site neutral payments; Issues related to PBM reforms; S. 1105, No UPCODE Act

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

AMGEN, INC. via AVENUE SOLUTIONS

2026 · second_quarter · Q2

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related To S. 5459, The Biosimilar Access and Affordability Act; Issues related to Senate Finance Dear Colleague process

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

AGRICULTURAL DRONE INITIATIVE (INFORMAL COALITION) via AVENUE SOLUTIONS

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to Physician Fee Schedule and physician payment reform; H.R. 879, Medicare Patient Access and Practice Stabilization Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services Act; Issues related to Provider Reimbursement Stability Act and Merit Based Incentive Payments System (MIPS) reform; Issues related to Senate Finance Dear Colleague process

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

TRD

Trade (domestic/foreign)

Issues related to drone competitiveness; Issues related to foreign-made drones

HOM

Homeland Security

Issues related to drone competitiveness

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

TAKEDA PHARMACEUTICALS AMERICA, INC. via AVENUE SOLUTIONS

2026 · second_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to drug pricing and reimbursement for prescription drugs.

COMPASS PATHWAYS, INC. via AVENUE SOLUTIONS

2026 · second_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to innovative treatment for mental health and PTSD.

AMGEN, INC. via AVENUE SOLUTIONS

2026 · second_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to drug pricing and reimbursement for prescription drugs.

VERTEX PHARMACEUTICALS INCORPORATED via AVENUE SOLUTIONS

2026 · first_quarter · Q1

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Monitor issues related to 340b; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC)

MMM

Medicare/Medicaid

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

SIEMENS MEDICAL SOLUTIONS USA, INC. via AVENUE SOLUTIONS

2026 · first_quarter · Q1

Firm income: $100,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC)

MMM

Medicare/Medicaid

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · first_quarter · Q1

Firm income: $70,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

SCAN HEALTH PLAN via AVENUE SOLUTIONS

2026 · first_quarter · Q1

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders

MMM

Medicare/Medicaid

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PARTNERSHIP FOR MEDICAID HOME-BASED CARE (PMHC) via AVENUE SOLUTIONS

2026 · first_quarter · Q1

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to Medicaid Home and Community-Based Services (HCBS); Issues related to Senate Finance Dear Colleague process

NATIONAL ALLIANCE FOR CARE AT HOME via AVENUE SOLUTIONS

2026 · first_quarter · Q1

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC)

MMM

Medicare/Medicaid

Medicare Home Health benefit; Medicaid Home and Community-Based Services (HCBS) benefits; Medicare Hospice benefit; Home Health Perspective Payment System (HH PPS) Final Rule for CY 2026 (CMS-1828-F); H.R. 3467, To amend title XVIII to reform the Medicare Advantage program; H.R. 5142, Home Health Stabilization Act of 2025; Hospice MA Carve-in

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · first_quarter · Q1

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to the Vaccine Injury Compensation Program (VICP); Issues related to vaccine safety and approval; Issues related to FDA's delay in reviewing Moderna's flu vaccine

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

MEDICAL INFORMATION TECHNOLOGY, INC. (MEDITECH) via AVENUE SOLUTIONS

2026 · first_quarter · Q1

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to the implementation of the Inflation Reduction Act of 2022; Issues related to Senate Finance Dear Colleague process

HCR

Health Issues

Issues related to vaccines; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC)

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · first_quarter · Q1

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to electronic health records; Issues related to Senator Wyden's letter to Electronic Health Record (EHR) companies and the adoption of privacy measures to protect patient data

Filing targets: SENATE

LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) via AVENUE SOLUTIONS

2026 · first_quarter · Q1

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to health workforce, including H1B visa and student loan reform

MMM

Medicare/Medicaid

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · first_quarter · Q1

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

HCR

Health Issues

Issues related to 340b; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC)

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · first_quarter · Q1

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to implementation of the Inflation Reduction Act of 2022

HCR

Health Issues

Drug safety, prescription drug abuse, value of prescription drugs; Issues related to drug pricing, including orphan drugs; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

HEMP INDUSTRY & FARMERS OF AMERICA (HIFA) via AVENUE SOLUTIONS

2026 · first_quarter · Q1

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

HCR

Health Issues

Issues related to 340b; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC)

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · first_quarter · Q1

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to hemp.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · first_quarter · Q1

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

HCR

Health Issues

Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC)

2026 · first_quarter · Q1

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Coverage of multi-cancer early detection tests; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC)

MMM

Medicare/Medicaid

H.R. 842/S. 339, Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · first_quarter · Q1

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

HCR

Health Issues

Issues related to 340b drug pricing program; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC)

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

DISTRICT OF COLUMBIA HOSPITAL ASSOCIATION via AVENUE SOLUTIONS

2026 · first_quarter · Q1

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders; Issues related to Senate Finance Dear Colleague process

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · first_quarter · Q1

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

TAX

Taxation/Internal Revenue Code

Issues related to DC taxes

MMM

Medicare/Medicaid

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

BLUE CROSS BLUE SHIELD ASSOCIATION via AVENUE SOLUTIONS

2026 · first_quarter · Q1

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to prescription drugs

MMM

Medicare/Medicaid

Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process

2026 · first_quarter · Q1

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to Medicare Advantage; Issues related to site neutral payments; Issues related to PBM reforms; S. 1105, No UPCODE Act

HCR

Health Issues

Healthcare affordability platform; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC); Issues related to Senate Finance Dear Colleague process

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · first_quarter · Q1

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to 2024 Physician Fee Schedule and physician payment reform; H.R. 879, Medicare Patient Access and Practice Stabilization Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services Act; Issues related to Provider Reimbursement Stability Act and Merit Based Incentive Payments System (MIPS) reform; Issues related to Senate Finance Dear Colleague process

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

MEDICAL INFORMATION TECHNOLOGY, INC. (MEDITECH) via AVENUE SOLUTIONS

2026 · first_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to prescription drugs.

HCR

Health Issues

Issues related to prescription drugs.

2026 · first_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to electronic medical records.

VERTEX PHARMACEUTICALS INCORPORATED via AVENUE SOLUTIONS

2025 · fourth_quarter · Q4

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Monitor issues related to 340b; Expiring healthcare extenders

MMM

Medicare/Medicaid

H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

SIEMENS MEDICAL SOLUTIONS USA, INC. via AVENUE SOLUTIONS

2025 · fourth_quarter · Q4

Firm income: $90,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues relating to Medicare Advantage, particularly as it relates to changes in coding intensity, benchmarks, and health risk assessments; Expiring healthcare extenders; Issues related to the use of AI and its correlation to prior authorization and utilization management policies; S. 1105, No UPCODE Act

HCR

Health Issues

Issues related to expiring healthcare extenders; Expiration of the ACA's Enhanced Premium Tax Credits (EPTCs)

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2025 · fourth_quarter · Q4

Firm income: $70,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Monitor issues related to site neutral payments; Monitor issues related to physician payment cuts; Monitor issues related to clinical lab tests; Monitor expiring healthcare extenders

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

SCAN HEALTH PLAN via AVENUE SOLUTIONS

2025 · fourth_quarter · Q4

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

HCR

Health Issues

Expiring healthcare extenders

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PARTNERSHIP FOR MEDICAID HOME-BASED CARE (PMHC) via AVENUE SOLUTIONS

2025 · fourth_quarter · Q4

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to Medicaid Home and Community-Based Services (HCBS)

NATIONAL ALLIANCE FOR CARE AT HOME via AVENUE SOLUTIONS

2025 · fourth_quarter · Q4

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

HCR

Health Issues

Expiring healthcare extenders; Expiring telehealth extender

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2025 · fourth_quarter · Q4

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to the Vaccine Injury Compensation Program (VICP); Issues related to vaccine safety and approval

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2025 · fourth_quarter · Q4

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to vaccines; Expiring healthcare extenders

MMM

Medicare/Medicaid

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to the implementation of the Inflation Reduction Act of 2022

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA) via AVENUE SOLUTIONS

2025 · fourth_quarter · Q4

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Expiring healthcare extenders; Issues related to CMS regulations and effect on Maryland hospitals; Issues related to the expiration of the ACA's APTC (Advanced Premium Tax Credit)

2025 · fourth_quarter · Q4

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

HCR

Health Issues

Issues related to 340b; Expiring healthcare extenders

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2025 · fourth_quarter · Q4

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Drug safety, prescription drug abuse, value of prescription drugs; Issues related to drug pricing; Expiring healthcare extenders; Issues related to BIOSECURE

MMM

Medicare/Medicaid

Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to implementation of the Inflation Reduction Act of 2022

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2025 · fourth_quarter · Q4

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to 340b; Expiring healthcare extenders; Issues related to Priority Review Voucher (PRV) program

MMM

Medicare/Medicaid

Issues related to Medicaid rebates; Issues related to Most Favored Nation (MFN) drug pricing proposal

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

HOUSE RX, INC. via AVENUE SOLUTIONS

2025 · fourth_quarter · Q4

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to H.R.2484 - Seniors Access to Critical Medications Act of 2025

HCR

Health Issues

Issues related to H.R.2484 - Seniors Access to Critical Medications Act of 2025

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2025 · fourth_quarter · Q4

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to home care and home and community based services (HCBS); Ensuring Access to Medicaid Services (CMS-2442-F)

HCR

Health Issues

Expiring healthcare extenders

2025 · fourth_quarter · Q4

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

H.R. 842/S. 339, Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

HCR

Health Issues

Expiring healthcare extenders

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2025 · fourth_quarter · Q4

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to 340b drug pricing program; Expiring healthcare extenders

MMM

Medicare/Medicaid

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

DISTRICT OF COLUMBIA HOSPITAL ASSOCIATION via AVENUE SOLUTIONS

2025 · fourth_quarter · Q4

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2025 · fourth_quarter · Q4

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to DC Hospitals and Medicaid formula; Expiring healthcare extenders; Issues related to the expiration of the ACA's APTC (Advanced Premium Tax Credit)

BLUE CROSS BLUE SHIELD ASSOCIATION via AVENUE SOLUTIONS

2025 · fourth_quarter · Q4

Firm income: $80,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Healthcare affordability platform; Issues related to the expiration of the ACA's APTC (Advanced Premium Tax Credit); Expiring healthcare extenders

MMM

Medicare/Medicaid

Issues related to Medicare Advantage; Issues related to site neutral payments; Issues related to PBM reforms; S. 1105, No UPCODE Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE